News

Dyax will present an analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations. The analysis will be

Mindray will also present demonstration units of six new products for 2009, including a surgical bed, surgical light, ceiling pendent system, WATO EX 30 anesthesia machine, BC-5800 hematology

The US Patent and Trademark Office (USPTO) has issued a patent to BioMarin Pharmaceutical (BioMarin) covering the approved administration of Kuvan (sapropterin dihydrochloride) with food for the treatment

Threshold Pharmaceuticals has disclosed clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS)

GlaxoSmithKline (GSK) and XenoPort has reported that the FDA has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug

NexBio in collaboration with scientists at the centers for disease control and prevention (CDC), has published two studies that suggests DAS181 (Fludase) may play a potentially important role

Graceway Pharmaceuticals (Graceway) has acquired the worldwide license, including related regulatory filings and intellectual properties from Gilead Sciences, to its’s investigational molecule, GS 9191, for topical use. GS

Intarcia has presented data for ITCA 650 (DUROS continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in

Genetix Pharmaceuticals has launched its clinical program to treat Adrenoleukodystrophy (ALD). It is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier